Evidence map›Paper›PMID 22749839›Full record

ArticleVaccine2012

Human papillomavirus vaccine knowledge and hypothetical acceptance among women in Appalachia Ohio.

Mack T Ruffin, Erinn M Hade, Melissa R Gorsline, Cecilia R DeGraffinreid, Mira L Katz, Sarah C Kobrin, Electra D Paskett

Registry-linked trialAbstract read
In one paragraph

Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02113514 (Community Awareness, Resources and Education), which is not on this map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02113514 completednot on this map

Community Awareness, Resources and Education (CARE I): Project 3

TypeobservationalSponsorOhio State University Comprehensive Cancer CenterRan2005 to 2009Enrolled2,394ConditionsCervical Abnormality
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Results of a Multilevel Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake among Adolescent Girls.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mack T RuffinDepartment of Family Medicine, University of Michigan, Ann Arbor, MI 48104-1213, United States. mruffin@umich.edu
Erinn M Hade
Melissa R Gorsline
Cecilia R DeGraffinreid
Mira L Katz
Sarah C Kobrin
Electra D Paskett

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
University of Iowa Clinical and Translational Science Program (TL1)UL1RR025755 · NCRR · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2008 to 2011
$26.3M
TRAINING AND CAREER DEVELOPMENTP50CA105632 · NCI · OHIO STATE UNIVERSITY · PI PASKETT, ELECTRA D. · 2003 to 2016
$17.2M
The Ohio State University Center for Clinical and Translational Science (UL1)UL1TR000090 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2012 to 2013
$7.9M
CANCER CHEMOPREVENTION &MENTORING CLINICAL RESEARCHERSK24CA080846 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RUFFIN, MACK T. · 1999 to 2010
$1.3M
Patient Activation To Increase Colon Cancer ScreeningK07CA107079 · NCI · OHIO STATE UNIVERSITY · PI KATZ, MIRA L · 2005 to 2009
$783k
NCATS NIH HHS UL1 TR000090NCI NIH HHS K07 CA107079NCI NIH HHS K24 CA080846NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA105632NCRR NIH HHS UL1 RR025755NCRR NIH HHS UL1RR025755
6 · The paper itself

Abstract

objectiveTo assess hypothetical acceptance of the human papillomavirus (HPV) vaccine for themselves and a daughter age 9-12 years among Appalachia Ohio women.

methodsWomen with an abnormal Pap smear and randomly selected women with a normal Pap smear from 17 clinics completed an interview in 2006-2008.

resultsFrom 1131 original study participants, 807 (71%) completed a survey about the HPV vaccine for their daughters and themselves. Nearly half, 380 (47%), of the participants had heard of a vaccine to prevent cancer, and 362 (95%) of respondents had heard of HPV. The participants were then told that the FDA had approved a vaccine to prevent HPV. Only 379 (38%) participants identified girls ages 9-12 years as a group who should get the vaccine. After being given the official HPV vaccine recommendation statement, 252 (31%) wanted the vaccine; 198 (25%) were "not sure"; and 353 (44%) did not want the vaccine for themselves. With respect to giving the HPV vaccine to a daughter ages 9-12 years, participants responded "yes" 445 (55%); "not sure" 163 (20%); or "no" 185 (23%). Numerous reasons were provided supporting and opposing vaccine acceptance for themselves and for a daughter. Their physician's recommendation for the HPV vaccine increased vaccine acceptance to 86% for themselves and 90% for a daughter.

conclusionKnowledge, acceptance, and barriers about the HPV vaccine vary among women living in Appalachia Ohio. Physician recommendation is a key facilitator for vaccine diffusion in this region.

Indexed as

Health Knowledge, Attitudes, PracticePapillomavirus VaccinesAdolescentAdultCase-Control StudiesChildFemaleHumansMiddle AgedOhioPapillomavirus InfectionsPatient Acceptance of Health CareSurveys and QuestionnairesUterine Cervical NeoplasmsYoung AdultPapillomavirus Vaccines

Identifiers

PMID22749839
PMCPMC3886268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.